Evaluation status available after sign-in
About the journal
ESMO Gastrointestinal Oncology is an open-access journal published by Elsevier in United Kingdom, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 3,480 USD. Declared review time at DOAJ: 16 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 2949-8198
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 3,480 USD
- Articles in DOAJ
- 296
- Declared review time
- 16 weeks
- Declared peer-review model
- other
Index listings
- DOAJ · 2024-07-04
- Indexing
- DOAJ
- APC
- 3,480 USD
- Declared review time (DOAJ)
- 16 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
296
Most recent article
last month
Average review time (journal-declared via DOAJ)
16weeks
Works in OpenAlex
287
Last recorded publication year
2026
Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
8
i10-index
7
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2024-07-04
- Declared plagiarism screening
- Not declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 91%
- ORCID iDs in current deposits
- 68%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 9919053637606676
Classification2
Subjects (DOAJ)
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
LCC codes
RC254-282
Subject areas
- Gastric Cancer Management and Outcomes
- Gastric Cancer Management and Outcomes
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Esophageal Cancer Research and Treatment
Show all subjects (75)
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Intraperitoneal and Appendiceal Malignancies
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
- HER2/EGFR in Cancer Research
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Head and Neck Cancer Studies
- Gallbladder and Bile Duct Disorders
- Gallbladder and Bile Duct Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Gallbladder and Bile Duct Disorders
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Educational Robotics and Engineering
- Colorectal Cancer Screening and Detection
- Human auditory perception and evaluation
- Human auditory perception and evaluation
- Colorectal Cancer Screening and Detection
- Educational Robotics and Engineering
- Barrier Structure and Function Studies
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Ferroelectric and Negative Capacitance Devices
- Big Data and Digital Economy
- Colorectal Cancer Screening and Detection
- Neuroendocrine Tumor Research Advances
- Ferroelectric and Negative Capacitance Devices
- Big Data and Digital Economy
- Metastasis and carcinoma case studies
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Ferroptosis and cancer prognosis
- Global Cancer Incidence and Screening
- Neuroendocrine Tumor Research Advances
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatitis Pathology and Treatment
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Cancer survivorship and care
Keywords (DOAJ)
- oncology
- gastrointestinal cancers
- cancer diagnostics
- immunotherapy
- epidemiology
- cancer prevention
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ